How a Bone Marrow Biopsy and Immune Testing Pin Down the Cause of Bone Marrow Failure

The phone call usually comes on an ordinary weekday. A routine blood test, repeated to be sure, still shows three cell lines drifting down at once. The word the doctor uses is “pancytopenia,” and the next word is “biopsy.” For most people that is the moment a vague tiredness and a few unexplained bruises turn into a question they never expected to ask: why has my marrow stopped doing its job?

A bone marrow biopsy for marrow failure is the test that starts to answer it. Blood counts describe the shipment leaving the warehouse; only a sample of the marrow shows whether the factory floor is empty, jammed with the wrong product or quietly on fire. Alongside it, a set of immune, viral and genetic tests looks for the reason.

This explainer walks through what each test does, what the sample looks like to the pathologist, and how a hematology team turns a stack of results into a name for what is happening, so that the conversation in the clinic feels less like a foreign language.

What causes bone marrow failure, and why does the cause matter so much?

Bone marrow is the soft tissue inside the larger bones where red cells, white cells and platelets are made from a small pool of stem cells. Marrow failure means that factory can no longer keep up: too few red cells brings anemia and breathlessness, too few neutrophils (the infection-fighting white cells) invites fevers, and too few platelets shows up as bruising or bleeding gums. When all three lines fall together, doctors call it pancytopenia.

The causes fall into a handful of families. In acquired aplastic anemia, the most common form in adults, the person’s own immune system attacks the stem cells, according to the National Heart, Lung, and Blood Institute. Inherited syndromes such as Fanconi anemia or dyskeratosis congenita carry a faulty gene that shortens the working life of those stem cells. Myelodysplastic syndromes (MDS) are clonal disorders, meaning one abnormal stem cell and its descendants crowd out healthy production and make poorly formed cells. Then come outside triggers: benzene and other solvents, radiation, some medicines and chemotherapy, and viral infections including hepatitis viruses, HIV, Epstein-Barr virus and parvovirus B19. Severe deficiency of vitamin B12, folate or copper can mimic marrow failure, and so can marrow crowded out by leukemia, lymphoma, scar tissue or spread from a solid cancer.

Why does sorting these apart matter? Because the paths diverge sharply. An immune attack may respond to medicines that quiet the immune system or to a stem cell transplant. Those same immune-suppressing medicines do little for an inherited syndrome, which needs a different transplant approach and testing of relatives. A clonal disorder follows its own guideline pathway, and a drug or chemical exposure calls for a careful review of what the person is taking, always with the prescriber rather than by stopping anything alone. The label matters less than the mechanism behind it.

Why a bone marrow biopsy for marrow failure is usually the decisive test

A complete blood count is a snapshot of cells already in circulation. It tells you the numbers are low, and a reticulocyte count (young red cells fresh out of the marrow) hints at whether the marrow is trying. A peripheral blood smear, where a technician looks at a drop of blood under the microscope, can pick up misshapen cells or stray immature cells. What none of these can do is show the marrow itself.

That distinction is the whole point. Low counts have two very different explanations. Either the marrow is not producing enough, or it is producing normally and the cells are being destroyed or trapped elsewhere, for example by an enlarged spleen or by antibodies. A bone marrow biopsy for marrow failure settles the question by looking directly at production. It also separates conditions that look identical on a blood test: an immune-driven aplastic anemia and a hypoplastic form of MDS can produce the same three low numbers, yet under the microscope one shows an almost empty, fatty marrow with normal-looking survivors and the other shows abnormal precursor cells or chromosome changes.

The sample does more than name the problem. It gives the team a baseline. Cellularity, the share of marrow space filled with blood-forming cells rather than fat, is graded and recorded so that a later biopsy can show whether the marrow is recovering, holding steady or evolving into something clonal. The aspirate portion also supplies living cells for the immune and genetic tests described later, which means one procedure feeds several laboratories at once. Cleveland Clinic and Mayo Clinic both describe the marrow examination as the reference test when blood counts cannot be explained, and in marrow failure that description is well earned.

Bone marrow aspiration vs biopsy: what is the difference?

People often hear “aspiration” and “biopsy” used as if they were the same thing. They are two samples, usually taken minutes apart through the same numbed patch of skin, and each answers questions the other cannot.

An aspiration uses a thin, hollow needle to draw out a small amount of liquid marrow. Spread on glass slides and stained, it lets the hematopathologist study individual cells in fine detail: how mature they are, whether they look normal, whether immature blast cells are more common than they should be. The same liquid sample is what the laboratory uses for flow cytometry, chromosome analysis and gene sequencing, because those tests need living, separated cells.

A biopsy, sometimes called a trephine or core biopsy, uses a slightly wider needle to remove a solid cylinder of bone with the marrow intact inside it. Roughly the size of a matchstick, this core preserves the architecture. It is the only reliable way to judge cellularity, to see whether scar tissue (fibrosis) is replacing normal marrow, and to spot clusters of foreign cells such as lymphoma or spread from another cancer.

In marrow failure the core is particularly important for a practical reason. When the marrow is nearly empty or fibrotic, the aspiration may come back as a “dry tap” or be diluted with blood, giving too few cells to judge. The core still shows how much marrow is really there. MedlinePlus describes the two procedures separately, but in practice a hematologist investigating low counts will almost always request both, so a person should expect two brief needle passes rather than one. Asking which samples are being taken, and why, is entirely reasonable.

What actually happens during a bone marrow biopsy for marrow failure

The procedure is shorter than most people imagine. Mayo Clinic puts the sampling itself at about 10 minutes, with the whole visit closer to half an hour once preparation and a short rest are included. Before starting, the team confirms consent, reviews medicines, especially blood thinners, and checks the latest blood count.

You lie on your side or stomach. The usual site is the posterior iliac crest, the broad ridge of hip bone you can feel just below the waistband at the back. The breastbone is used only occasionally, and only for aspiration, because the hip is safer and gives a better core. The skin is cleaned and a local anesthetic is injected into the skin and the surface of the bone, which stings for a few seconds. Some centers offer a mild sedative or, for children and anxious adults, a deeper sedation; if so, someone else needs to drive you home.

For the aspiration, the needle passes through the numbed bone surface into the marrow cavity and a syringe draws back the liquid. This is the part people describe as a brief, deep, pulling ache that lasts a few seconds and cannot be fully numbed, because the anesthetic does not reach the inside of the bone. For the core, a slightly larger needle is advanced and rotated, which feels like firm pressure rather than sharp pain. Once both samples are out, the needle is removed and firm pressure is applied, then a dressing.

You rest lying on your back for a short while so the dressing presses on the site, and then most people walk out. If the marrow is very low in platelets the nurse may hold pressure longer and watch a little more closely before you leave.

Who is usually offered the biopsy, and who is asked to wait

Hematologists do not reach for the needle at the first low number. They usually offer a marrow examination when counts are low in two or more cell lines without an obvious explanation, when a single line is severely and persistently low, when the blood smear shows abnormal or immature cells, when someone needs repeated transfusions, or when a specific condition such as aplastic anemia, MDS, leukemia or PNH is on the shortlist and the marrow is the only way to tell them apart.

Being asked to wait is common, and it is not a brush-off. A dip in counts after a viral illness, or soon after starting a new medicine, often recovers within a couple of weeks and is rechecked rather than biopsied. Simple blood tests for vitamin B12, folate and copper levels, thyroid and liver function, and markers of red cell destruction are usually completed first, because a deficiency or a peripheral cause changes the plan and may make the biopsy unnecessary. Alcohol intake and recent chemotherapy are also weighed.

Very low platelets are, on their own, not usually a reason to postpone. The hip site can be compressed directly, so bleeding is generally controlled by pressure, and the information is needed most in exactly those patients. Anticoagulant or antiplatelet medicines are a different matter: the prescribing clinician decides whether and how they should be paused, and that decision belongs to them, not to the person taking them. A skin infection over the hip, difficulty lying still, or pregnancy prompt adjustments in timing or technique rather than cancellation. For children, the pathway is the same but the sampling is typically done under sedation or general anesthesia with a parent present before and after.

Aplastic anemia diagnosis: what the pathologist looks for under the microscope

The core and the slides reach a hematopathologist, a doctor who specializes in blood and marrow tissue. The first judgment is cellularity. Healthy marrow is a mixture of blood-forming cells and fat, and it becomes fattier with age, so the pathologist compares what they see with what is expected for someone of that age rather than against a single fixed standard.

In aplastic anemia the marrow is strikingly hypocellular. Fat fills spaces that should be busy, and the few remaining cells are mostly lymphocytes and plasma cells scattered like the last guests at a party. Crucially, the survivors look normal. That normality is what separates aplastic anemia from its main look-alike, hypoplastic MDS, where the marrow is also sparse but the precursor cells are misshapen (dysplastic), immature blasts may be more numerous than expected, and chromosome analysis often turns up an abnormality.

Special stains widen the search. A reticulin stain reveals fibrosis, the scar tissue that can strangle production in myelofibrosis. An iron stain shows whether iron is being stored or wasted. Immunohistochemistry, which uses antibodies to color specific cell types, can reveal a hidden lymphoma or a nest of cells that traveled from a solid cancer elsewhere. Granulomas, small clusters of inflammatory cells, raise the possibility of an infection such as tuberculosis.

Aplastic anemia diagnosis then moves beyond the slide. International guidelines grade severity by combining how empty the marrow is with the neutrophil count, platelet count and reticulocyte count into non-severe, severe and very severe categories. The exact cutoffs are set out in those guidelines, and the treating team will explain which category applies. That grade, more than any single number, shapes how urgently treatment decisions are made and which options are on the table.

How immune testing looks for an immune attack on the marrow

Here is the frustrating truth about acquired aplastic anemia: there is no single blood test that catches the immune system in the act. The NHLBI describes the disease as an attack by the person’s own T lymphocytes on their stem cells, but that attack leaves no simple fingerprint. The diagnosis is therefore made partly by exclusion and partly by finding supporting clues.

The most useful clue comes from flow cytometry. Flow cytometry passes cells one by one through a laser beam and counts them by the proteins on their surface. In paroxysmal nocturnal hemoglobinuria (PNH), a condition MedlinePlus describes as arising when an acquired gene change in a stem cell leaves blood cells missing the protective proteins normally anchored to their surface, those unprotected cells are vulnerable to destruction by the body’s complement system. A small population of PNH-type cells is often found alongside aplastic anemia, and its presence supports an immune-mediated process rather than an inherited or clonal one. A larger PNH population can explain dark urine, clots or ongoing red cell breakdown and may need attention in its own right.

Around that central test sit others. Viral serologies look for hepatitis viruses, HIV, Epstein-Barr virus, cytomegalovirus and parvovirus B19, any of which can suppress marrow. An autoantibody screen is added when lupus or another autoimmune disease is plausible. If red cells are being destroyed, a direct antiglobulin test checks for antibodies coating them. Flow cytometry and T-cell receptor studies can identify an expanded population of large granular lymphocytes, a distinct disorder that sometimes drives cytopenias.

One more test is often ordered early even though it does not diagnose anything: HLA typing, which records a person’s tissue type. It is the first step in finding a matched donor should a transplant ever be discussed, and doing it early avoids delay later.

Genetic and chromosome tests: inherited syndromes and clonal disease

The aspirate’s living cells go to two more laboratories. The cytogenetics lab grows the cells briefly, halts them mid-division and photographs the chromosomes as a karyotype. Missing, extra or rearranged chromosomes, such as loss of chromosome 7, point toward MDS or a related clonal disorder rather than a pure immune attack. FISH, which uses fluorescent probes to light up specific chromosome regions, can find targeted changes even when cells refuse to grow.

The molecular lab runs next-generation sequencing, reading dozens of genes known to be altered in myeloid diseases. Interpreting the result takes judgment. Small populations of cells carrying such changes become more common with age in healthy people, so a single finding rarely settles anything on its own. What matters is the pattern, the size of the abnormal population and how it fits with the microscope findings.

Inherited bone marrow failure syndromes call for a separate set of tests, and adults are not exempt: a milder inherited condition can surface for the first time in the twenties or thirties. For Fanconi anemia, the chromosome breakage test exposes blood cells to a DNA-damaging chemical and looks for excessive breaks, because the faulty genes in this condition impair DNA repair, as MedlinePlus explains. For dyskeratosis congenita and related telomere disorders, telomere length is measured; telomeres are the protective caps on chromosome ends, and in these conditions they are abnormally short. Germline gene panels, run on blood or sometimes on skin cells to avoid contamination by an abnormal blood clone, confirm the specific gene involved.

Finding an inherited cause changes a great deal: transplant conditioning is adjusted because these patients are unusually sensitive to chemotherapy and radiation, relatives may be offered testing, and long-term surveillance for other complications is planned. Mayo Clinic notes that specialized tests of this kind take longer than the basic slide review, often weeks rather than days.

Putting the results together: what each test can and cannot tell you

No single result names the cause. The hematologist lays the pieces side by side, and the table below shows how each one contributes and where it falls silent.

Test	Sample	Main question it answers	What it cannot tell you
Blood count and reticulocytes	Blood	Which lines are low and whether the marrow is trying	Why they are low
Blood smear	Blood	Shape of cells, stray immature cells	Marrow cellularity
Marrow aspirate	Liquid marrow	Cell maturation, dysplasia, blast proportion	Architecture, fibrosis; may be dry in failure
Core biopsy	Bone cylinder	Cellularity, fibrosis, infiltration	Fine cell detail, genetics
Flow cytometry	Blood or aspirate	PNH-type cells, abnormal lymphocyte or blast populations	Inherited causes
Karyotype and FISH	Aspirate	Chromosome changes suggesting a clonal disorder	Small gene mutations
Gene sequencing	Aspirate or blood	Acquired mutations, pattern of clonal disease	Significance of an isolated finding
Breakage test, telomere length, germline panel	Blood or skin	Inherited marrow failure syndrome	Acquired immune attack
Viral and autoimmune serology	Blood	Infectious or autoimmune trigger	Whether the trigger is still active in marrow
HLA typing	Blood	Tissue type for possible donor matching	Anything about the diagnosis

Reading across the rows, a typical acquired aplastic anemia picture is an empty core, normal-looking survivors, normal chromosomes, a small PNH population and negative inherited-syndrome tests. Abnormal chromosomes or clear dysplasia tilt toward MDS. A positive breakage test or very short telomeres reframes everything as inherited. When the picture stays ambiguous, the team may repeat the marrow examination after some weeks rather than guess, and many centers review difficult cases in a multidisciplinary meeting before settling on a name.

Bone marrow biopsy recovery time: what the days and weeks afterward look like

The first hours are about pressure and rest. After a short period lying on the dressing, most people go home the same day. MedlinePlus advises keeping the dressing dry for about 24 hours, and Mayo Clinic suggests avoiding vigorous activity for a day or two to reduce the risk of bleeding at the site. Anyone who had sedation should not drive, operate machinery or sign important documents until the next day.

Soreness at the back of the hip is expected. Mayo Clinic notes that tenderness can last a week or more, and people often describe it as a deep bruise that complains when they sit on a hard chair or roll over in bed. Because some common pain relievers affect platelets, ask the team which ones are suitable rather than reaching for whatever is in the cupboard. A small bruise is normal; a spreading one is not, and the red-flag section below covers that.

Results arrive in layers. Mayo Clinic explains that the slide review usually comes back within a few days, while flow cytometry follows soon after and chromosome and gene studies can take longer, often a few weeks for the specialized tests. Inherited-syndrome tests may be the last to report. This staggered timeline is the hardest part of bone marrow biopsy recovery time for many people: the body heals quickly while the answer is still forming.

During the wait, care continues. Transfusions may be given for symptoms of anemia or for very low platelets, infection precautions are explained, and a follow-up appointment is booked to go through everything together. Occasionally the first sample is inadequate or the picture is unclear, and a repeat marrow examination is requested. That is a sign of thoroughness, not of something having gone wrong.

Risks and alternatives, described plainly

A marrow examination is a low-risk procedure, but not a risk-free one, and the team should walk through the possibilities before you sign.

Bleeding at the site is the most relevant risk in marrow failure, because platelets are often very low. In practice it is uncommon and usually controlled by firm pressure, since the hip bone lies just under the skin where it can be compressed. Infection can occur where the needle passed, which is why the skin is cleaned carefully and the dressing kept dry. Pain that lingers longer than expected happens in a minority of people. Injury to nearby nerves or blood vessels is rare at the hip; the breastbone carries a small but serious risk to the structures behind it, which is one reason the hip is preferred. Sedative medicines, when used, bring their own small risk of breathing or blood pressure changes, which is why you are monitored.

What are the alternatives? For a mild or recent drop in counts with a likely explanation, repeating blood tests over a couple of weeks is a genuine alternative and is often what the team chooses. Several of the immune and genetic tests, including flow cytometry for PNH cells, viral serology and germline gene panels, can be run on a blood sample without any marrow at all. Imaging such as MRI can show broad changes in marrow fat content but cannot judge cellularity, spot dysplasia or find a small abnormal clone, so it does not replace tissue.

Once counts are persistently and unexplainably low, there is no alternative that provides the same information about production and architecture. Declining the biopsy is always a person’s right, and the team’s job is to explain what would remain unknown as a result and to leave the decision with the patient and their clinicians.

What people often get wrong about marrow failure testing

Misunderstandings cluster around this procedure, and clearing them up tends to lower the temperature in the room.

“The needle goes into my spine.” It does not. The sample comes from the back of the hip bone, well away from the spinal cord. The confusion comes from lumbar puncture, a different test on a different structure.

“With platelets this low, a biopsy is too dangerous.” Low platelets are the usual situation in marrow failure, and the hip site can be compressed directly. The team weighs the risk, but a low count on its own is rarely a reason to skip the test.

“Marrow failure means leukemia.” Leukemia is one cause among many. An empty, immune-attacked marrow, an inherited syndrome, a viral trigger or a nutritional deficiency are all on the list, and the biopsy exists precisely to tell them apart.

“Aplastic anemia is a cancer.” It is not. Guidelines describe it as an immune-mediated failure of production. A small proportion of people later develop a clonal disorder, which is why follow-up marrow examinations are planned, but the condition itself is not a malignancy.

“My counts were normal a year ago, so it can’t be inherited.” Some inherited syndromes present in adulthood after decades of adequate function. Age alone does not rule them out, which is why breakage and telomere tests are considered even in adults.

“The biopsy gives the answer.” The biopsy gives the picture. The answer comes from combining that picture with immune, viral, chromosome and genetic results, and sometimes with a second look weeks later.

“Eating more iron will fix it.” Iron helps only iron-deficiency anemia. In marrow failure the problem is production, not raw material, and unnecessary iron can add to the iron load that transfusions already bring.

Questions to ask your care team

A good consultation leaves you knowing what is being looked for, not just what is being done. Writing questions down beforehand helps, and bringing someone to listen alongside you helps more. Consider asking:

• Which conditions are you trying to distinguish with this marrow examination, and which findings would point to each?
• Will you take both an aspirate and a core, and which laboratories will receive the samples?
• Which of my current medicines, supplements or herbal products should I mention, and do any need to be adjusted by the prescriber before the procedure?
• Is sedation available or advisable for me, and will I need someone to take me home?
• Which immune tests are being sent, and are you testing for PNH-type cells, viral causes and autoimmune markers?
• Are chromosome studies and gene sequencing included, and are inherited marrow failure syndromes being considered given my age and family history?
• Should HLA typing be done now, and would my siblings be asked for a sample?
• When will each set of results be back, and who will contact me if something needs urgent attention before the follow-up appointment?
• What symptoms should prompt me to call before then, and which number do I use out of hours?
• If the first sample is unclear, how likely is a repeat, and when would it happen?
• Once a diagnosis is reached, which guideline pathway would you expect to follow, and what options would be on the table?
• Are there decisions I should be thinking about now, such as travel, work or vaccinations, while I wait?

None of these questions second-guesses the team. They signal that you want to be a partner in a process that will unfold over weeks, and most hematologists welcome exactly that.

When to call your doctor

Two sets of warning signs matter: those from the procedure itself, and those from the underlying low counts, which do not pause while results are pending.

After the biopsy, call the team the same day if bleeding from the site does not stop after 10 minutes of firm, steady pressure, if a bruise is spreading or the area is swelling, if redness, warmth, pus or increasing pain develops around the puncture over the following days, or if you notice new numbness, tingling or weakness in the leg on that side. Pain that is getting worse rather than better after the first few days also deserves a call.

Because of the marrow failure, treat certain symptoms as urgent regardless of the biopsy. A temperature of 38 °C (100.4 °F) or higher, chills or feeling suddenly unwell when neutrophils are low is an emergency, because infection can progress rapidly without enough white cells; the CDC uses this threshold for fever in people with low neutrophil counts. Seek immediate care for bleeding that will not stop, blood in urine or stool, black tarry stools, vomiting blood, a sudden severe headache, confusion, changes in vision or speech, chest pain, severe breathlessness, fainting, or a rapidly increasing rash of tiny red or purple dots. Dark, cola-colored urine, especially first thing in the morning, should be reported promptly, as it can signal red cell breakdown.

If you cannot reach your hematology team out of hours, go to the nearest emergency department and say clearly that you have low blood counts under investigation and a recent marrow biopsy. Carrying a card or a note on your phone with your latest counts and the team’s contact details makes that conversation faster. Every decision about treatment, including whether to change or pause any medicine, rests with the clinicians looking after you.

Frequently asked questions

What causes bone marrow failure in adults who were previously healthy?

In adults, the most common cause of acquired aplastic anemia is an immune attack on the marrow’s stem cells, according to the NHLBI. Other causes include exposure to benzene, radiation or certain medicines, viral infections such as hepatitis or Epstein-Barr virus, clonal disorders like MDS, and severe vitamin B12, folate or copper deficiency. A late-presenting inherited syndrome is also possible, which is why genetic tests are considered.

How is an aplastic anemia diagnosis actually confirmed?

Aplastic anemia is confirmed when the marrow core is markedly hypocellular for the person’s age, the remaining cells look normal, and tests for other causes such as MDS, leukemia, inherited syndromes, infections and deficiencies come back negative. Flow cytometry showing a small PNH-type population supports the diagnosis. Severity is then graded using guideline cutoffs that combine cellularity with neutrophil, platelet and reticulocyte counts.

Bone marrow aspiration vs biopsy: do I need both?

Usually yes. The aspiration draws liquid marrow for detailed cell study, flow cytometry, chromosome analysis and gene sequencing. The biopsy removes a small core of bone that preserves the marrow’s structure and is the only reliable way to judge cellularity, fibrosis and infiltration. In marrow failure the aspirate may be dry or diluted, so the core becomes essential. Both are taken through the same numbed site.

How long does a bone marrow biopsy take, and does it hurt?

Mayo Clinic puts the sampling itself at about 10 minutes and the whole appointment at roughly half an hour including preparation and a short rest. The local anesthetic stings briefly, and the aspiration causes a deep, pulling ache for a few seconds that cannot be fully numbed. The core feels like firm pressure. Sedation can be offered, particularly for children or anxious adults.

What is the typical bone marrow biopsy recovery time?

Most people go home the same day and return to normal activities within a day or two, while avoiding vigorous exercise over that period as Mayo Clinic advises. MedlinePlus recommends keeping the dressing dry for about 24 hours. Tenderness at the back of the hip can last a week or more. Results arrive in stages, from a few days for the slide review to several weeks for genetic tests.

Is it safe to have a bone marrow biopsy with very low platelets?

Low platelets are the usual situation in marrow failure and are rarely a reason to skip the test on their own. The hip site lies directly under the skin and can be compressed firmly, so bleeding is generally controlled by pressure. The team may hold pressure longer and observe you for a while afterward. Any blood-thinning medicine is a separate question that the prescribing clinician decides.

Why is a PNH flow cytometry test ordered when my problem is low counts?

Paroxysmal nocturnal hemoglobinuria (PNH) arises when some blood cells lack protective surface proteins and become vulnerable to destruction by the complement system. A small population of these cells is often found alongside aplastic anemia and supports an immune-mediated cause. A larger population can explain dark urine, clots or ongoing red cell breakdown and may need attention in its own right, so the test informs both diagnosis and follow-up.

Can bone marrow failure be inherited even if nobody in my family has it?

Yes. Inherited syndromes such as Fanconi anemia and dyskeratosis congenita can arise from new gene changes or be passed on by parents who have no symptoms, and milder forms may not surface until adulthood. That is why chromosome breakage tests, telomere length measurement and germline gene panels are considered in adults with unexplained marrow failure, not only in children. Finding an inherited cause changes transplant planning and prompts testing of relatives.

Is aplastic anemia a type of cancer?

No. Aplastic anemia is a failure of blood cell production, most often driven by the immune system, and it is not a malignancy. It can look similar to hypoplastic myelodysplastic syndrome under the microscope, which is one reason chromosome and gene tests are run. A minority of people with aplastic anemia later develop a clonal disorder, so hematologists plan periodic follow-up marrow examinations to watch for that change.

What happens if the first bone marrow biopsy result is inconclusive?

An inconclusive result usually means the aspirate was too diluted, the core was too small, or the findings sat between two diagnoses. The team may send additional tests on blood, review the case in a multidisciplinary meeting, or repeat the marrow examination after some weeks to see how the picture has evolved. Meanwhile, supportive care such as transfusions and infection precautions continues under the hematology team’s direction.

References

• Bone marrow biopsy (MedlinePlus Medical Encyclopedia)
• Paroxysmal nocturnal hemoglobinuria (MedlinePlus Genetics)
• Fanconi anemia (MedlinePlus Genetics)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.